Month: August 2012

August 13, 2012
EMA Calls for Further Research on Personalized Approaches to Treating Hemophilia

The European Medicines Agency (EMA) has released a new reflection paper on the risks of adverse immune system reactions in hemophilia patients treated with Factor VIII products and how these factors might be mitigated in the future. EMA explains in its 31 July reflection paper that up to 30% of patients with severe hemophilia A …

Read article